Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Industry Organization
EntreMed CEO testifies before House Committee on Sarbanes-Oxley reform
June 2nd, 2006
James S. Burns, president and CEO of Rockville, Maryland-based EntreMed Inc., recently testified on behalf of the Biotechnology Industry Organization (BIO) regarding the unintended consequences of Sarbanes-Oxley, the corporate governance law. Burns delivered his remarks before the House Committee on Small Business in a hearing titled "Sarbanes-Oxley Section 404: What is the Proper Balance Between Investor Protection and Capital Formation for Smaller Public Companies'" Burns' discussion focused on the need to reform Section 404, which applies a "one-size-fits-all" approach to internal controls for all publicly traded companies. Complying with Section...
Source: Medicine & Law Weekly (2006-06-02)
|
